



SUCCESS STORIES



2 BRIDGE

Science to Life

About the Client



A Belgian biopharmaceutical company developing a novel approach to the treatment of chronic autoimmune and inflammatory diseases.

AT A GLANCE

- A preclinical stage biotech founded in 2019
- A spin-off from University of Nantes and INSERM (France)
- The company's novel and unique therapeutic approaches induce immune tolerance and preserve useful immune responses in inflammatory, autoimmune, and degenerative diseases.
- Therapeutic areas in focus: autoimmune diseases (RA, APECED, Sjogren, SLE, GVHD...)

Challenges

The young biotech was founded by three scientists in France in November 2019, right before COVID-19.

2 Bridge was brought on board by the investors before the seed funding to build the company's corporate management, Research & Development team and navigate the young company through the complex and challenging life science landscape.



Small Seed Fund at the Start

- Small seed fund at the start
- Hindered research and development
- Limited scalability



Global Pandemic Environment

- Reduced access to fund raising during economic turbulence
- Strengthened travel restrictions



Novel Mechanism of Action

- Extensive research, followed by new data
- Heightened regulatory scrutiny




From a University Spinoff to a Commercial Biotech

- Adapting from academic research to commercial product development
- Limited knowledge for business acume

Tiger Team Approach

A 2 Bridge Tiger Team, including seasoned healthcare executives and R&D experts, covering general management, finances, preclinical, and clinical development, was assembled to complement the company's existing scientific founders and other consultants.



Outcome

Over the course of 2.5 years, different key milestones have been achieved...

01

Optimized and completed the preclinical package for lead candidate selection



02

Obtained scientific input from the regulatory agency



03

Designed the clinical protocol for the First-in-Human (FIH) trial



04

Finalized a successful series A financing of 27,3M€



05

Opened a new office in the BioPark of Gosselies, Belgium



06

Launched a brand-new website



07

Next Steps:

- CTA submission
- GMP production, formulation for Phase 1 clinical trial



Testimonial

“When we met the 2 Bridge Tiger Team, they immediately understood our vision, needs and challenges to translate our scientific goals into a successful company. We were impressed by their organization, their approach and ability to bridge the gap and bring on board the people with the right expertise and strong experience. Their dedication and commitment to excellence has had a significant impact on our organization and their efforts significantly contributed not only on the growth and progress of our company but also in the successful series A funding of 27 million euros. The 2 Bridge Tiger Team has not only met but exceeded our expectations, I would highly recommend them to any company venturing into life sciences.”



Dr. Carole Guillonneau, PhD

Scientific Founder & Head of Research at AbolerIS Pharma